Effect Of Anti-HER-2 Engineered Antibody ChA21 On Human Breast Cancer And Ovarian Cancer Cells And Its Mechanism

Background and Objective Breast cancer and ovarian cancer are the most common cancers to affect women, and there are no effective therapeutic approaches for the diseases in spite of advances in surgery, chemotherapy, and radiotherapy. Effective treatments for the two cancers are urgently needed. HER-2, also known as c-erbB-2 or neu, is localized to chromosome 17q and encodes a 185KD transmembrane tyrosine kinase receptor protein that is a member of the epidermal growth factor receptor family. The high frequency of HER-2 over-expression on the surface of breast cancer and ovarian cancer (a location that makes the molecule accessible to antibodies), together with its unfavorable prognostic significance, provided fundamental rationale for the development of a biological therapy to target HER-2 specifically, of which monoclonal antibodies (MAb) against HER-2 are paradigmatic. For this reason, our research group developed three strains of murine MAb A18, A21, and A22 which direct against...